PRNewsWire
03 Jun 2026, 10:45 UTC · 2h ago
Medtronic reports fourth quarter and full year fiscal 2026 results; delivers highest annual revenue growth in 10 years
Search tags
PRNewsWire
03 Jun 2026, 10:45 UTC · 2h ago
Search tags
Story key points
5 claims · impact-rated
Medtronic provides FY27 guidance for organic revenue growth of 6.75% to 7.25% and non-GAAP EPS growth of 6.7% to 8.5%. — Forward-looking guidance is the primary driver of stock valuation, and projecting growth in both top and bottom lines is strongly positive.
+0.60Medtronic achieved its highest annual revenue growth in 10 years for fiscal year 2026. — Decadal peak growth signals a successful strategic turnaround or strong product demand, increasing investor confidence in the business model.
+0.50The company increased its quarterly cash dividend to $0.72 per share, marking 49 consecutive years of increases. — Dividend growth is a positive signal of financial health and a draw for income-focused investors.
+0.30Continue reading
6 related stories
Q4 non-GAAP diluted EPS decreased by 4.3% and non-GAAP operating margins decreased by 230 basis points. — Short-term contraction in profitability and margins offsets some of the positivity from top-line growth.
FY26 non-GAAP operating margins were pressured by 50 basis points from tariffs and 45 basis points from a MiniMed Blackstone payment. — Highlights specific external cost headwinds (tariffs) that can act as a drag on future profitability.
-0.10Ticker attribution
Model heads
The company reported its highest annual revenue growth in 10 years, increased its dividend for the 49th consecutive year, and provided positive FY27 guidance.
No ticker relationship head found.
Early access
News Impact Screener scores every headline against the stocks it moves — before the chart reacts. Join the early-access list and get alerted the moment a story hits your tickers.
Impact vectors
9 dimensions · 9 clusters
Market reaction
10 bid · 0 offered
No stock impact ranking available yet.
Seeking Alpha
1h ago
